Search Results

You are looking at 1 - 7 of 7 items for :

  • "adjuvant immunotherapy" x
  • Refine by Access: All x
Clear All
Full access

Paul B. Chapman

High dose interferon-α (HD IFN) is approved by the United States Food and Drug Administration for adjuvant treatment of patients with stage III melanoma after complete surgical resection. Despite this, clinicians and patients around the world and in many parts of the US have failed to embrace this treatment option because of the lack of overall survival benefit and minimal other clinical benefits seen in randomized trials, combined with the therapy's substantial toxicity. This article reviews the data from the randomized trials that lead to this conclusion and discuss why arguments often advanced in favor of using HD IFN are not persuasive. New treatment options are needed for adjuvant therapy of melanoma. In the meantime, the data from the randomized trials make it difficult for many clinicians and patients to have enthusiasm for adjuvant HD IFN.

Full access

Michael S. Sabel and Vernon K. Sondak

allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma . Ann Surg Oncol 2002 ; 9 : 486 – 492 . 47 Sondak VK Liu PY Tuthill RJ . Adjuvant immunotherapy of resected, intermediate-thickness, node

Full access

Leslie A. Fecher and Keith T. Flaherty

melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine . Ann Surg 1992 ; 216 : 463 – 482 . 41 Sondak V Liu P Tuthill R . Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an

Full access

Anthony J. Olszanski

exciting results in the adjuvant setting: relapse-free survival was significantly increased in patients with fully resected stage III disease (based on AJCC 7th edition) with a BRAF V600E/K mutation. 7 Adjuvant Immunotherapy The addition of immunotherapy

Full access

Justin Famoso, Gerald Lemole, Srinath Sundararajan, and Baldassarre Stea

maximal safe resection followed by focal radiation and adjuvant immunotherapy is both safe and effective. References 1. Wendel C , Kaech DL , Woodtli M . Primary malignant melanoma in the pineal region: case report and literature review . J

Full access

Tobin Strom, Javier F. Torres-Roca, Akash Parekh, Arash O. Naghavi, Jimmy J. Caudell, Daniel E. Oliver, Jane L. Messina, Nikhil I. Khushalani, Jonathan S. Zager, Amod Sarnaik, James J. Mulé, Andy M. Trotti, Steven A. Eschrich, Vernon K. Sondak, and Louis B. Harrison

.277–2.399; P <.001), nodal size >2 cm (HR, 1.405; 95% CI, 1.045–1.889; P =.02), and adjuvant immunotherapy (to be reported separately). OS by RSI Status To assess whether a gene signature of radiosensitivity could help identify which patients might

Full access

David Y. Oh, Alan P. Venook, and Lawrence Fong

adjuvant immunotherapy with BCG and neuraminidase-treated autologous tumour cells in large bowel cancer . J Surg Oncol 1989 ; 40 : 34 – 37 . 18. Hoover HC Jr Brandhorst JS Peters LC . Adjuvant active specific immunotherapy for human